Autoimmune Cytopenia Elimination by Chimeric Antigen Receptor T-cell Therapy

Part of paid clinical trials in Stanford, California.

Sponsor
Saurabh Dahiya
Study ID
NCT07790575
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cytopenia

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • AZD0120 — DRUG
    One time administration on Day 0.
  • Bendamustin — DRUG
    Participants will be given bendamustin for 2 days (study Day -5 and Day -4) followed by 3 days of rest.

Study Details

This is a phase 1 study to evaluate the safety and tolerability of AZD0120 in patients with relapsed or refractory immune mediated cytopenia (primary chronic Immune Thrombocytopenia (ITP) or autoimmune hemolytic anemia (wAIHA)).

Key Dates

First listed
Aug 27, 2026
Start date
Sep 30, 2026
Status verified
Aug 2026
Primary completion
Jul 31, 2041
Completion
Jul 31, 2041

Study Design

Enrollment
16 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
OTHER

Arms

  • Experimental: AZD0120 (cell therapy product) + Bendamustine
    Participants receive AZD0120 (CAR-T therapy product) on Day 0 and Bendamustine for 2 days prior to the CAR-T therapy administration.
  • Experimental: AZD0120 (cell therapy product)
    Participants receive AZD0120 (CAR-T therapy product) on Day 0.

Primary Outcome Measure

Incidence of adverse events [ Time Frame: within 28 days after the CAR-T administration ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford UniversityStanfordCalifornia94305-

Find similar trials in Stanford, CA

By research site
Stanford University· Stanford, CA

Related Studies